Pliant Therapeutics, Inc.
PLRXNASDAQHealthcare● Active
$1.15
+$0.00(+0.00%)
Market Cap$71208230
P/E Ratio—
52W High$1.95
52W Low$1.09
Pliant Therapeutics, Inc. (PLRX) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · PLRX · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.00B | $0.01B | $0.01B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | ($0.00B) | $0.00B | $0.00B | $0.01B | $0.01B |
| Gross Margin %(computed) | — | — | 100.00% | 100.00% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $0.11B | $0.17B | $0.13B | $0.10B | $0.08B |
| G&A Expenses | $0.05B | $0.06B | $0.06B | $0.04B | $0.03B |
| Total Operating Expenses | $0.15B | $0.23B | $0.19B | $0.14B | $0.11B |
| Operating Income | ($0.15B) | ($0.23B) | ($0.18B) | ($0.13B) | ($0.10B) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.00B | $0.02B | $0.02B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.15B) | ($0.21B) | ($0.16B) | ($0.12B) | ($0.10B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.15B) | ($0.21B) | ($0.16B) | ($0.12B) | ($0.10B) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-2.43 | $-3.47 | $-2.75 | $-2.94 | $-2.71 |
| Wtd Avg Shares | 0.06B | 0.06B | 0.06B | 0.04B | 0.04B |
| EBITDA | ($0.15B) | ($0.21B) | ($0.16B) | ($0.12B) | ($0.10B) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · B
Explore more Pliant Therapeutics, Inc. data
About Pliant Therapeutics, Inc. (PLRX) Income Statement
Pliant Therapeutics, Inc. (PLRX) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, PLRX reported revenue of $0.00B, gross profit of ($0.00B) (gross margin —), and net income of ($0.15B) — a net profit margin of —.
Frequently asked questions
PLRX · 4 questionsPliant Therapeutics, Inc. (PLRX) reported revenue of $0.00B for 2025, down —% year-over-year.
PLRX revenuePLRX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09